113 related articles for article (PubMed ID: 20622519)
1. Only one-third of girls receive HPV vaccine.
Hum Vaccin; 2010 Jul; 6(7):525. PubMed ID: 20622519
[No Abstract] [Full Text] [Related]
2. Free school-based vaccination with HPV vaccine in a Japanese city.
Fujiwara H; Suzuki M; Yoshinari T; Shiiya K
Vaccine; 2011 Sep; 29(38):6441-2. PubMed ID: 21704106
[No Abstract] [Full Text] [Related]
3. Considerations for human papillomavirus (HPV) vaccination of mid-adult women in the United States.
Grant LA; Dunne EF; Chesson H; Markowitz LE
Vaccine; 2011 Mar; 29(13):2365-70. PubMed ID: 21277406
[TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus vaccines: an update for gynecologists.
Ault KA
Clin Obstet Gynecol; 2008 Sep; 51(3):527-32. PubMed ID: 18677145
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus immunisation of adolescent girls and anticipated reporting of immune-mediated adverse events.
Callréus T; Svanström H; Nielsen NM; Poulsen S; Valentiner-Branth P; Hviid A
Vaccine; 2009 May; 27(22):2954-8. PubMed ID: 19428906
[TBL] [Abstract][Full Text] [Related]
6. Predictors of HPV vaccine uptake among women aged 19-26: importance of a physician's recommendation.
Rosenthal SL; Weiss TW; Zimet GD; Ma L; Good MB; Vichnin MD
Vaccine; 2011 Jan; 29(5):890-5. PubMed ID: 20056186
[TBL] [Abstract][Full Text] [Related]
7. Compliance with recommended dosing intervals for HPV vaccination among females, 13-17 years, National Immunization Survey-Teen, 2008-2009.
Dorell CG; Stokley S; Yankey D; Markowitz LE
Vaccine; 2012 Jan; 30(3):503-5. PubMed ID: 22119587
[TBL] [Abstract][Full Text] [Related]
8. Barriers prevent HPV vaccination in low-income populations.
AIDS Patient Care STDS; 2010 Jan; 24(1):70. PubMed ID: 20169639
[No Abstract] [Full Text] [Related]
9. A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US.
Dunne EF; Datta SD; E Markowitz L
Cancer; 2008 Nov; 113(10 Suppl):2995-3003. PubMed ID: 18980283
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women.
Garcia-Sicilia J; Schwarz TF; Carmona A; Peters K; Malkin JE; Tran PM; Behre U; Iturbe EB; Catteau G; Thomas F; Dobbelaere K; Descamps D; Dubin G;
J Adolesc Health; 2010 Feb; 46(2):142-51. PubMed ID: 20113920
[TBL] [Abstract][Full Text] [Related]
11. [Implementation of HPV vaccination in Germany].
Schreckenberger C; Kaufmann AM; Schneider A
Dtsch Med Wochenschr; 2007 Oct; 132(42):2221-4. PubMed ID: 17926251
[No Abstract] [Full Text] [Related]
12. Opinions of parents about school-entry mandates for the human papillomavirus vaccine.
Horn L; Howard C; Waller J; Ferris DG
J Low Genit Tract Dis; 2010 Jan; 14(1):43-8. PubMed ID: 20040835
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls.
Medina DM; Valencia A; de Velasquez A; Huang LM; Prymula R; García-Sicilia J; Rombo L; David MP; Descamps D; Hardt K; Dubin G;
J Adolesc Health; 2010 May; 46(5):414-21. PubMed ID: 20413076
[TBL] [Abstract][Full Text] [Related]
14. Oral human papillomavirus (HPV) infection--are there implications for HPV vaccination?
Sourvinos G; Mammas IN; Spandidos DA
J Infect Dis; 2010 Feb; 201(3):478; author reply 478-9. PubMed ID: 20059358
[No Abstract] [Full Text] [Related]
15. Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands.
Boot HJ; Wallenburg I; de Melker HE; Mangen MJ; Gerritsen AA; van der Maas NA; Berkhof J; Meijer CJ; Kimman TG
Vaccine; 2007 Aug; 25(33):6245-56. PubMed ID: 17630049
[TBL] [Abstract][Full Text] [Related]
16. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
[TBL] [Abstract][Full Text] [Related]
17. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing.
Schiffman M
Cancer; 2007 Jun; 111(3):145-53. PubMed ID: 17487850
[TBL] [Abstract][Full Text] [Related]
18. HPV 16/18 prevalence reduced 3 years following vaccine introduction.
Riedmann EM
Hum Vaccin Immunother; 2014; 10(2):254. PubMed ID: 24963520
[No Abstract] [Full Text] [Related]
19. High HPV vaccine acceptance despite low awareness among Swedish upper secondary school students.
Gottvall M; Larsson M; Höglund AT; Tydén T
Eur J Contracept Reprod Health Care; 2009 Dec; 14(6):399-405. PubMed ID: 19929642
[TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus vaccine initiation among adolescent girls in high-risk communities.
Guerry SL; De Rosa CJ; Markowitz LE; Walker S; Liddon N; Kerndt PR; Gottlieb SL
Vaccine; 2011 Mar; 29(12):2235-41. PubMed ID: 21288799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
